Pasar al contenido principal

FIBROSIS DEL TEJIDO ADIPOSO:REGULACION E IMPACTO EN LA DISFUNCION TISULAR Y COMUNICACION INTERORGANOS EN OBESIDAD Y RESISTENCIA A INSULINA

PID2022-141964OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE CORDOBA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of the new EASO obesity definition on the detection of atheromatosis in subjects with low-to-moderate cardiovascular risk

  • León-Mengíbar, Josep|||0000-0002-5982-3461
  • Bermúdez-López, Marcelino|||0000-0002-3188-4158
  • Valdivielso, José Manuel|||0000-0003-1343-0184
  • Pamplona, Reinald|||0000-0003-4337-6107
  • Torres, Gerard|||0000-0002-1417-7320
  • Mauricio, Didac|||0000-0002-2868-0250
  • Castro-Boqué, Eva|||0000-0002-1013-0007
  • Fernández, Elvira|||0000-0001-5236-1762
  • Caixàs i Pedragós, Assumpta|||0000-0001-8472-9189
  • Bueno, Marta|||0000-0001-9488-4553
  • Ciudin, Andreea|||0000-0001-5622-0203
  • Hernández García, Marta|||0000-0003-1237-298X
  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Hernández, Cristina|||0000-0002-3109-1721
  • Lecube, Albert|||0000-0001-9684-0183
Traditional body mass index (BMI) does not adequately reflect adipose tissue distribution and associated cardiovascular (CV) risk. To improve risk stratification, the European Association for the Study of Obesity (EASO) proposes to extend the diagnosis of obesity to include individuals with a BMI of 25-30 kg/m², a waist-to-height ratio (WtHR) ≥0.5, and any obesity-related complication. To examine whether this new definition of obesity can better identify the presence of subclinical atheromatosis disease (SAD) in terms of arterial plaque burden compared to the classical BMI-based definition. A cross-sectional including 8,330 participants from the ILERVAS project (ClinicalTrials.gov Identifier: ), aged 45-70 years with low-to-moderate CV risk and no previous CV disease, was included. Obesity was classified using traditional (BMI ≥ 30 kg/m²) and new definitions. Atherosclerosis was assessed through Doppler ultrasound of carotid and femoral arteries. Logistic regression models adjusted for cardiovascular risk factors were used to evaluate associations between obesity definitions and SAD. The new definition increased obesity prevalence from 37.2% to 71.7%. It also revealed higher detection of atheromatous plaques (72.9% vs. 68.6%, p.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Association of estimated liver fibrosis with carotid but not femoral atherosclerotic burden: the ILERVAS cohort

  • León Mengíbar, Josep
  • Malagón, María
  • Bermúdez López, Marcelino
  • Valdivielso Revilla, José Manuel
  • Pamplona Gras, Reinald
  • Torres Cortada, Gerard
  • Mauricio Puente, Dídac
  • Castro Boqué, Eva
  • Fernández, Elvira
  • Caixàs, Assumpta
  • Hernández García, Marta
  • López Cano, Carolina
  • Gordon, Ana
  • Guzman Ruiz, Rocio
  • Cusi, Kenneth
  • Lecube Torelló, Albert
Introduction: Advanced liver fibrosis, a key complication of metabolic dysfunction-associated steatotic liver disease, has been increasingly linked to extrahepatic conditions, including type 2 diabetes, obesity, and cardiovascular disease. However, the specific association of liver fibrosis in the development and progression of subclinical atheromatous disease across vascular territories remains poorly understood. This study evaluates the utility of two non-invasive indices to predict liver fibrosis and their associations with subclinical atheromatous plaque burden and distribution. Methods: Atheromatous plaque burden (plaque presence, number, and total area) was assessed in the carotid and femoral territories via ultrasonography in 3,981 middle-aged participants without known cardiovascular disease, diabetes, or liver disease from the ILERVAS cohort (ClinicalTrials.gov Identifier: NCT03228459). The fibrosis-4 (FIB-4) and the NAFLD Fibrosis Score (NFS) were evaluated. FIB-4 risk categories were defined as low (<1.30), intermediate (1.30–2.67), and high (>2.67). Results: Participants in the intermediate and high-risk FIB-4 categories exhibited a higher prevalence of carotid atheromatous disease (56.8% vs. 49.5%, p<0.001), a greater number of plaques (p<0.001), and a larger total plaque area (p=0.007). Multivariable analyses confirmed FIB-4 as an independent predictor of carotid plaque burden (OR: 1.14, 95% CI 1.05-1.24, p=0.003), even adjusting for traditional cardiovascular risk factors. Moving from low to high FIB-4 cut-offs was associated with 12.6% higher odds of carotid atherosclerosis. NFS was also independently associated with carotid atheromatosis (OR 1.10, 95% CI 1.05–1.15, p<0.001). No significant associations were found in the femoral territory for either index. Conclusions: Estimated liver fibrosis, particularly FIB-4, is a valuable marker for identifying carotid subclinical atherosclerosis in populations without known liver disease. These findings highlight the importance of vascular territory-specific evaluations and support their utility in integrated liver and cardiovascular risk assessment strategies., The author(s) declared that financial support was received for this work and/or its publication. This research was supported by grant PI21/00462 (Institute of Health Carlos III, European Regional Development Fund, “A way to build Europe). Authors in the study also participate in this other grants: PI21/01099, PMP21/00109, PMP22/00073, PI23/00237 and RD24/0004/0015 (Instituto de Salud Carlos III, European Regional Development Fund, “A way to build Europe), PID2022-141964OB-I00 (Ministerio de Ciencia, Innovación y Universidades, co-funded by the European Regional Development Fund, “A way to build Europe”).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Association of estimated liver fibrosis with carotid but not femoral atherosclerotic burden: the ILERVAS cohort

  • León Mengíbar, Josep
  • Malagón, María
  • Bermúdez López, Marcelino
  • Valdivielso Revilla, José Manuel
  • Pamplona Gras, Reinald
  • Torres Cortada, Gerard
  • Mauricio Puente, Dídac
  • Castro Boqué, Eva
  • Fernández, Elvira
  • Caixàs, Assumpta
  • Hernández García, Marta
  • López Cano, Carolina
  • Gordon, Ana
  • Guzman Ruiz, Rocio
  • Cusi, Kenneth
  • Lecube Torelló, Albert
Introduction: Advanced liver fibrosis, a key complication of metabolic dysfunction-associated steatotic liver disease, has been increasingly linked to extrahepatic conditions, including type 2 diabetes, obesity, and cardiovascular disease. However, the specific association of liver fibrosis in the development and progression of subclinical atheromatous disease across vascular territories remains poorly understood. This study evaluates the utility of two non-invasive indices to predict liver fibrosis and their associations with subclinical atheromatous plaque burden and distribution. Methods: Atheromatous plaque burden (plaque presence, number, and total area) was assessed in the carotid and femoral territories via ultrasonography in 3,981 middle-aged participants without known cardiovascular disease, diabetes, or liver disease from the ILERVAS cohort (ClinicalTrials.gov Identifier: NCT03228459). The fibrosis-4 (FIB-4) and the NAFLD Fibrosis Score (NFS) were evaluated. FIB-4 risk categories were defined as low (<1.30), intermediate (1.30–2.67), and high (>2.67). Results: Participants in the intermediate and high-risk FIB-4 categories exhibited a higher prevalence of carotid atheromatous disease (56.8% vs. 49.5%, p<0.001), a greater number of plaques (p<0.001), and a larger total plaque area (p=0.007). Multivariable analyses confirmed FIB-4 as an independent predictor of carotid plaque burden (OR: 1.14, 95% CI 1.05-1.24, p=0.003), even adjusting for traditional cardiovascular risk factors. Moving from low to high FIB-4 cut-offs was associated with 12.6% higher odds of carotid atherosclerosis. NFS was also independently associated with carotid atheromatosis (OR 1.10, 95% CI 1.05–1.15, p<0.001). No significant associations were found in the femoral territory for either index. Conclusions: Estimated liver fibrosis, particularly FIB-4, is a valuable marker for identifying carotid subclinical atherosclerosis in populations without known liver disease. These findings highlight the importance of vascular territory-specific evaluations and support their utility in integrated liver and cardiovascular risk assessment strategies., The author(s) declared that financial support was received for this work and/or its publication. This research was supported by grant PI21/00462 (Institute of Health Carlos III, European Regional Development Fund, “A way to build Europe). Authors in the study also participate in this other grants: PI21/01099, PMP21/00109, PMP22/00073, PI23/00237 and RD24/0004/0015 (Instituto de Salud Carlos III, European Regional Development Fund, “A way to build Europe), PID2022-141964OB-I00 (Ministerio de Ciencia, Innovación y Universidades, co-funded by the European Regional Development Fund, “A way to build Europe”).